CORDIS
EU research results

CORDIS

English EN

Models Of Patient Engagement for Alzheimer’s Disease - Sofia ref.: 115985

Project information

Grant agreement ID: 115985

Status

Closed project

  • Start date

    1 October 2016

  • End date

    31 December 2019

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 4 581 967,80

  • EU contribution

    € 2 043 000

Coordinated by:

FUNDACIO ACE

Spain

Objective

The MOPEAD consortium has proposed a programme of work carefully aligned to the objectives of IMI2 Call to deliver a step-change in AD-related patient engagement (PE) strategies and a paradigm shift in early stage care. It aims to improve patient engagement in three categories: 1) Pre-clinical AD (the most important for prevention trials; 2) Prodromal AD (i.e. MCI with positive amyloid biomarkers); and 3) Very Mild AD. MOPEAD offers four different and complementary strategies, namely AD Citizen-Science, Open House Initiative (OHI), Primary Care Campaign (PCC), and Type 2 Diabetes (T2DM). It seeks subjects eligible for CT scan in all three mentioned categories. The central concept is to test and evaluate the four Patient Engagement models (Runs) to help identify patients at risk of AD in a five-country, multi-centre setting. It builds upon an already successful model, the Open House Initiative pioneered by the coordinator (FACE). Five countries (ES, DE, NL, SE and SL) have been selected to implement these models based upon relevant expertise; the consortium brings together partners for their potential to become long-term assets to European efforts to tackle AD challenges. The methodology involves enhanced pre-screening protocols to select individuals for conventional screening associated to an RCT. Eligible subjects will be invited to formal evaluation using a protocol consensus with EPFIA. MOPEAD possesses confident baseline metrics from which to measure progress and determine the efficacy of PE strategies compared to primary care. Although baseline data exists for only three of the four proposed models, the new model AD Citizen Science approach will add significantly to the holistic approach of the project. The proposal addresses the specific cross-border challenge of improving health care and reducing the economic burden related to AD by means of identifying those patients at risk of developing AD. This will cover a significant gap in the healthcare system.

Coordinator

FUNDACIO ACE

Address

Marques De Sentmenat 57
08014 Barcelona

Spain

Activity type

Research Organisations

EU Contribution

€ 311 684,93

Participants (14)

Eli Lilly and Company Limited

United Kingdom

ASDM CONSULTING

Belgium

EU Contribution

€ 118 299,31

ASTRAZENECA AB

Sweden

EUROPEAN INSTITUTE OF WOMEN'S HEALTH COMPANY LIMITED BY GUARANTEE

Ireland

EU Contribution

€ 45 688

GMV SOLUCIONES GLOBALES INTERNET SAU

Spain

EU Contribution

€ 380 593,75

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 468 701,73

KITE INNOVATION (EUROPE) LIMITED

United Kingdom

EU Contribution

€ 34 538,49

SPOMINCICA ALZHEIMER SLOVENIJA SLOVENSKO ZDRUZENJE ZA POMOC PRI DEMENCI

Slovenia

EU Contribution

€ 25 991,43

KLINIKUM DER UNIVERSITAET ZU KOELN

Germany

EU Contribution

€ 144 106,90

UNIVERZITETNI KLINICNI CENTER LJUBLJANA

Slovenia

EU Contribution

€ 168 306,79

FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA

Spain

EU Contribution

€ 74 322,40

STICHTING VUMC

Netherlands

EU Contribution

€ 97 347,69

ALZHEIMER EUROPE

Luxembourg

EU Contribution

€ 91 275

MODUS RESEARCH AND INNOVATION LIMITED

United Kingdom

EU Contribution

€ 82 143,58

Project information

Grant agreement ID: 115985

Status

Closed project

  • Start date

    1 October 2016

  • End date

    31 December 2019

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 4 581 967,80

  • EU contribution

    € 2 043 000

Coordinated by:

FUNDACIO ACE

Spain